Fredrik Nilsson

a pfizer ab, access and value, stockholm, swedencorrespondencefredrik.nilsson@pfizer.com https://orcid.org/0000-0002-1905-4047view further author information

H指数:27

被引数:2,965

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Follow-up of incidentally detected mild to moderate ascending aortic dilation and risk factors for rapid progression in a Swedish middle-aged population

HEART

IF4.4

2025-03-010

PRE

Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir/ritonavir versus usual care in Swedish patients with various risk factors

瑞姆特雷韦/利托那韦与常规护理相比，在具有各种风险因素的瑞典患者中门诊COVID-19抗病毒治疗的经济效益分析

JOURNAL OF MEDICAL ECONOMICS

IF3

2025-01-170

First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population

FUTURE ONCOLOGY

IF2.6

2024-10-280

Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population

FUTURE ONCOLOGY

IF2.6

2024-07-260

OAAI

Wall shear stress measured with 4D flow CMR correlates with biomarkers of inflammation and collagen synthesis in mild-to-moderate ascending aortic dilation and tricuspid aortic valves

EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING

IF6.6

2024-05-151

OAAI

Cost-Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer in Sweden

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2023-05-127

OAAI

SentiDose interim analysis. A dose optimizing study with a super paramagnetic iron oxide for sentinel node detection

CANCER RESEARCH

IF16.6

2019-02-150

PRE

SentiDose - A dose optimizing study with SiennaXP, a superparamagnetic iron oxide for sentinel node detection

EUROPEAN JOURNAL OF CANCER

IF7.1

2018-04-010

PREAI

Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease: A systematic review and meta-analysis

阿片类药物对慢性阻塞性肺疾病患者呼吸困难和运动能力影响的系统评价和meta分析

EUROPEAN RESPIRATORY JOURNAL

IF21

2015-10-302

PRE

Effects of Opioids on Breathlessness and Exercise Capacity in Chronic Obstructive Pulmonary Disease A Systematic Review

阿片类药物对慢性阻塞性肺疾病患者呼吸困难和运动能力影响的系统评价

ANNALS OF THE AMERICAN THORACIC SOCIETY

IF5.4

2015-07-01158

PREAI

REIMBURSEMENT DECISIONS FOR PHARMACEUTICALS IN SWEDEN: THE IMPACT OF COST-EFFECTIVENESS AND DISEASE SEVERITY

VALUE IN HEALTH

IF6

2014-11-010

OAAI

A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial

ANNALS OF ONCOLOGY

IF65.4

2013-09-015

OAAI

Personalizing health care: feasibility and future implications

BMC MEDICINE

IF8.3

2013-08-1369

OAAI

Godman, Brian; Finlayson, Alexander E.; Cheema, Parneet K.; Zebedin-Brandl, Eva; Gutierrez-Ibarluzea, Inaki; Jones, Jan; Malmstrom, Rickard E.; Asola, Elina; Baumgartel, Christoph; Bennie, Marion; Bishop, Iain; Bucsics, Anna; Campbell, Stephen; Diogene, Eduardo; Ferrario, Alessandra; Fuerst, Jurij; Garuoliene, Kristina; Gomes, Miguel; Harris, Katharine; Haycox, Alan; Herholz, Harald; Hviding, Krystyna; Jan, Saira; Kalaba, Marija; Kvalheim, Christina; Laius, Ott; Loeoev, Sven-Ake; Malinowska, Kamila; Martin, Andrew; McCullagh, Laura; Nilsson, Fredrik; Paterson, Ken; Schwabe, Ulrich; Selke, Gisbert; Sermet, Catherine; Simoens, Steven; Tomek, Dominik; Vlahovic-Palcevski, Vera; Voncina, Luka; Wladysiuk, Magdalena; van Woerkom, Menno; Wong-Rieger, Durhane; Zara, Corrine; Ali, Raghib; Gustafsson, Lars L.

How to differentiate by price: Proposal for a five-dimensional model

EUROPEAN MANAGEMENT JOURNAL

IF7.3

2013-04-0124

OAAI

A DETAILED COMPARISON OF DUTCH AND SWEDISH DRUG REIMBURSEMENT DECISIONS: WHAT EVIDENCE IS AVAILABLE, WHICH CRITERIA ARE USED, AND IS THE DECISION-MAKING PROCESS TRANSPARENT?

VALUE IN HEALTH

IF6

2012-11-010

OAAI

Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry

BJU INTERNATIONAL